Blood Culture G+ (25 targets)
Blood Culture G+ (25 targets)

[Product Name]

25 Blood Culture Pathogen and Antimicrobial Resistance Gene (G+&Fungi&AMR) Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

Blood Culture G+ (25 targets)  CHE-BCIP25-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Blood Culture G+ (25 targets) Chenghui-Multi-Disc-25-Blood-Culture-Gram-Positive-Fungi-AMR-Nucleic-Acid-Detection-Kit-Brochure.pdf


No Data

Testing Process

No Data

Intended Use


25 Blood Culture Pathogen and Antimicrobial Resistance Gene (G+&Fungi&AMR) Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of Gram-positive bacterial and fungal pathogens and their antimicrobial resistance genes in positive blood culture samples from patients with bloodstream infections. The pathogens that can be detected include:

  1. Enterococcus faecalis, 

  2. Enterococcus faecium, 

  3. Listeria monocytogenes, 

  4. Staphylococcus spp., 

  5. Staphylococcus aureus, 

  6. Staphylococcus epidermidis, 

  7. Streptococcus spp., 

  8. Streptococcus agalactiae, 

  9. Streptococcus pneumoniae, 

  10. Streptococcus pyogenes, 

  11. PVL-producing Staphylococcus aureus, 

  12. Candida albicans, 

  13. Candida auris, 

  14. Candida glabrata, 

  15. Candida krusei, 

  16. Candida parapsilosis, 

  17. Candida tropicalis, 

  18. Cryptococcus (C. neoformans/C. gattii), 

  19. Aspergillus fumigatus,

  20. Pan-Fungal. 


The antimicrobial resistance genes that can be detected include: 

  1. vanA, 

  2. vanB, 

  3. mecA, 

  4. mecC,

  5. SSCmec-orfX.


Clinical Challenges


Bloodstream infections (BSIs) and sepsis are life-threatening critical conditions, with mortality rising sharply for every hour of delayed effective antimicrobial therapy. For tertiary hospital intensive care units, hematology departments and clinical microbiology laboratories, conventional diagnostic workflows for positive blood cultures have four core unmet clinical needs:


Prolonged identification and susceptibility testing delays life-saving targeted therapy, especially for fungal infections

After blood culture flags positive, traditional workflows require 24–72 hours for subculture, isolate identification and antimicrobial susceptibility testing (AST) for Gram-positive bacteria. For fungal pathogens such as Aspergillus and slow-growing Candida species, testing can take 3–7 days. Clinicians must rely on empiric broad-spectrum antimicrobial and antifungal therapy during this window, leading to higher treatment failure rates, elevated sepsis mortality and extended hospital length of stay.


Rising Gram-positive resistance and refractory fungal infections pose severe clinical challenges

Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) remain highly prevalent in inpatient settings, while multidrug-resistant fungi such as Candida auris carry major nosocomial transmission risks. Conventional AST results lag far behind clinical demand, resulting in inappropriate empiric treatment and poor patient outcomes.


Low sensitivity of traditional fungal detection leads to high missed diagnosis rates

Conventional blood culture has limited sensitivity for invasive fungal pathogens, particularly Aspergillus fumigatus and fastidious fungal strains, causing frequent missed diagnoses in immunocompromised patients (e.g., hematology, transplant and oncology populations). Delayed targeted antifungal therapy is directly associated with drastically higher mortality.


Fragmented workflows lack an integrated, flexible rapid BSI diagnostic framework

Existing full-spectrum molecular panels come with high per-test costs, while single-target assays deliver low efficiency. There is a lack of matched rapid testing solutions aligned with Gram stain results, leaving no cohesive, cost-effective rapid diagnostic system for severe bloodstream infection cases.


Core Clinical Benefits


The 25 Blood Culture Pathogen and Antimicrobial Resistance Gene (G+&Fungi&AMR) Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above critical care pain points:


Blood Culture G+ (25 targets) One-stop Gram-positive pathogen, fungal pathogen and resistance gene profiling

The kit covers 11 clinically prevalent Gram-positive BSI pathogens, 9 fungal targets (including Pan-Fungal) and 5 core antimicrobial resistance genes, totaling 25 targets. A single run delivers simultaneous identification of Gram-positive bacteria, fungi and associated resistance markers, drastically improving diagnostic efficiency for both bacterial and fungal bloodstream infections.


Results in around 80 minutes to capture the sepsis golden treatment window

Total testing time is around 80 minutes, with only 1 minute of hands-on sample loading — 1–3 days faster than traditional culture and AST workflows, with an even greater speed advantage for fungal detection. Rapid pathogen and resistance results enable clinicians to promptly adjust empiric regimens to targeted antibacterial or antifungal therapy, reduce sepsis mortality, shorten hospital stays and lower overall healthcare costs.


Targeted resistance gene coverage to guide precision antimicrobial therapy

The panel detects core Gram-positive resistance markers including mecA, mecC and SSCmec-orfX for rapid MRSA identification, as well as vanA and vanB for VRE detection. Early identification of drug-resistant strains supports precise antibiotic selection, optimizes antimicrobial stewardship and curbs the spread of nosocomial drug-resistant pathogens.


Complementary workflow with G-&AMR panel to build a complete rapid BSI diagnostic system

This G+&Fungi&AMR kit is clinically paired with our 26-target Blood Culture Pathogen and Antimicrobial Resistance Gene (G-&AMR) Detection Kit. For routine workflows, laboratories can select the corresponding panel based on Gram stain results immediately after blood culture flags positive — this Gram-aligned targeted testing balances diagnostic efficiency and cost. For critically ill septic patients or immunocompromised hosts with suspected mixed infections, both panels can be run in parallel on the Multi-Disc platform in a single batch to deliver full-spectrum pathogen and resistance coverage, providing a comprehensive, rapid etiological diagnostic framework for severe bloodstream infections.


Low-barrier POCT deployment to reduce diagnostic turnaround time

Powered by the fully automated closed Multi-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be deployed directly in ICUs, hematology departments and clinical microbiology labs. Positive blood culture samples can be tested immediately upon flagging, eliminating transport delays and compressing overall diagnostic turnaround time (TAT).


Core Product Advantages


Critical care-oriented 25-plex panel tailored for Gram-positive and fungal BSIs

The panel is designed for inpatient severe bloodstream infection scenarios, covering high-prevalence Gram-positive pathogens (including S. aureus, PVL-producing S. aureus, Streptococcus pneumoniae, enterococci and Listeria monocytogenes) and clinically critical fungal pathogens (6 Candida species including C. auris, Cryptococcus, Aspergillus fumigatus and Pan-Fungal). All resistance targets are selected for direct clinical therapeutic guidance, fully aligned with the needs of tertiary hospital ICUs, hematology, transplant and infectious disease departments.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.

Blood Culture G+ (25 targets)


Flexible throughput with dual-panel compatibility for diverse clinical needs

Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. The system supports mixed runs of G+&Fungi&AMR and G-&AMR panels in a single batch, flexibly accommodating positive blood culture samples with different Gram stain results, and meeting both stat critical care and routine batch testing demands.


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and operational costs for microbiology labs and critical care departments.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures accurate, reliable results for positive blood culture samples.


CE-compliant with validated positive blood culture compatibility

The assay is fully validated for positive blood culture samples. All 25 targets are CE-marked, meeting regulatory requirements for clinical BSI diagnosis, antimicrobial stewardship and nosocomial infection control across global markets.